Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06360653

a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer

a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer (SISTER-RAY)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
ARNAS Civico Di Cristina Benfratelli Hospital · Academic / Other
Sex
Female
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The primary endpoint of the present prospective study is to assess the outcomes in terms of acute toxicity of post-operative stereotactic radiotherapy for endometrial cancer

Detailed description

Endometrial cancer represents the sixth global female cancer, and adjuvant radiotherapy has a main role in the management of these patients. This treatment usually covers the surgical bed, the upper portion of the vagina and the pelvic lymph nodes. In the last decades, the technological progress has allowed clinicians to offer a more accurate planning and delivery of the treatment with modern IMRT-IGRT techniques. Nonetheless, radiotherapy regimens were still based on 25-30 fractions schedules. More recently, similarly to other oncological settings like prostate, breast or rectal cancer, 5-fractions schedules have been considered as potentially useful also in this setting. On this purpose, this study aims to investigate the feasibility of a shorter adjuvant radiotherapy treatment for endometrial cancer, by assessing acute and late toxicity, quality of life and clinical outcomes.

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic Post-operative Radiotherapy for Endometrial CancerPatients candidate to receive adjuvant radiotherapy will be assigned to a shorter schedule of 30 Gy in 5 sessions.

Timeline

Start date
2025-05-02
Primary completion
2026-05-01
Completion
2027-05-01
First posted
2024-04-11
Last updated
2025-06-25

Locations

2 sites across 1 country: Italy

Source: ClinicalTrials.gov record NCT06360653. Inclusion in this directory is not an endorsement.